Raiyaan Khaja

Highly motivated and detail-oriented clinical researcher with a Bachelor's degree in Biomedical Science and a solid background in medical science. Possessing four years of experience in clinical documentation, data entry, and clinical practice implementations, Eager to leverage expertise and passion for advancing healthcare through research in a dynamic clinical research role. Adept at analyzing and interpreting complex medical data, Committed to ensuring the integrity, quality, and compliance of clinical trials. With exceptional organizational skills and a strong analytical mindset, Dedicated to contributing to the success of cutting-edge research initiatives and playing a vital role in improving patient outcomes.

• Basic Life Support(BLS)
• Good Clinical Practice (GCP)
• International Air Transport Association (IATA)
• OSHA Blood Bourne Pathogens
• Edmonton Frail Scale (EFS)
• Clinical Documentation
• Qualitative & Quantitative Research
• Quality Control
• Quality Assurance
• Informed Consent
• HIPAA
• Management
• Phlebotomy
• EKG obtainment

• Phase III, Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa.
• Phase III, Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants with Plaque Psoriasis.
• Phase III, Study to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males.
• Phase II, Study of the Efficacy, Tolerability, and Safety of Oral Sulopenem Etzadroxil/Probenecid versus Oral Amoxicillin/Clavulanate for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women.
• Phase III, Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients with Fibromyalgia.
• Phase III, Study to Evaluate the Immunogenicity, Reactogenicity and Safety of mRNA1010 Seasonal Influenza Vaccine in Adults 18 years and older.
• Phase I/II, Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-based Influenza and SARS-CoV-2 Multicomponent Vaccines in Healthy Adults.
• Phase III, Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared with mRNA-1273.222 in Participants Aged 12 years and older for the Prevention of COVID-19.
• Phase III, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-dose, Quadrivalent Seasonal Influenza Vaccine in Adults ≥65 Years of Age.
• Phase III, Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1083 (SARS-CoV-2 and influenza) Vaccine in Healthy Adult Participants, ≥ 50 years of Age.